Section Arrow
BTAI.NASDAQ
- BioXcel Therapeutics
(Financial Status)
Quotes are at least 15-min delayed:2025/01/12 03:17 EST
Last
 0.3773
-0.0082 (-2.13%)
Day High 
0.383 
Prev. Close
0.3855 
1-M High
0.5785 
Volume 
833.09K 
Bid
0.3601
Ask
0.3943
Day Low
0.351 
Open
0.37 
1-M Low
0.3001 
Market Cap 
19.13M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.41 
20-SMA 0.4 
50-SMA 0.5 
52-W High 4.17 
52-W Low 0.3001 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.04/-0.75
Enterprise Value
120.17M
Balance Sheet
Book Value Per Share
-1.73
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.38M
Operating Revenue Per Share
0.02
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CDTConduit Pharmaceuticals0.1233+0.0413+50.37%-- 
MRSNMersana Therapeutics0.72-0.58-44.62%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.2787+0.0227+8.87%-- 
ZVSAZyVersa Therapeutics1.47+0.29+24.58%0PE
SANASana Biotechnology3.66-0.64-14.88%-- 
Quotes are at least 15-min delayed:2025/01/12 03:17 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology.The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.